Lerusse Julien, Uginet Marjolaine, Théaudin Marie, Bernard-Valnet Raphaël, Pot Caroline, Lalive Patrice H
Unité de neuro-immunologie, Service de neurologie, Département des neurosciences cliniques, Hôpitaux universitaires de Genève et Faculté de médecine, Université de Genève, 1211 Genève 14.
Service de neurologie, Département des neurosciences cliniques, Centre hospitalier universitaire vaudois et Université de Lausanne, 1011 Lausanne.
Rev Med Suisse. 2024 Apr 24;20(871):828-832. doi: 10.53738/REVMED.2024.20.871.828.
Myelin Oligodendrocyte Glycoprotein Antibody Associated Disease (MOGAD) is an autoimmune disease responsible for demyelination of the central nervous system that can occur in adults or children. Overlapping phenotypes between MOGAD, multiple sclerosis (MS) and neuromyelitis optica spectrum disease (NMOSD) have been described. The diagnostic criteria for MOGAD were proposed by a panel of international experts and published in 2023. Defining clinical, biological and imaging characteristics specific to this entity helps to improve diagnostic specificity. In this article, we present the clinical characteristics suggestive of MOGAD and discuss the importance of the antibody detection method and therapeutic management.
髓鞘少突胶质细胞糖蛋白抗体相关疾病（MOGAD）是一种自身免疫性疾病，可导致中枢神经系统脱髓鞘，可发生于成人或儿童。已有文献报道MOGAD、多发性硬化（MS）和视神经脊髓炎谱系疾病（NMOSD）之间存在重叠的表型。MOGAD的诊断标准由一组国际专家提出并于2023年发表。明确该疾病特有的临床、生物学和影像学特征有助于提高诊断特异性。在本文中，我们介绍了提示MOGAD的临床特征，并讨论了抗体检测方法和治疗管理的重要性。
